0001213900-24-004799.txt : 20240119 0001213900-24-004799.hdr.sgml : 20240119 20240119143325 ACCESSION NUMBER: 0001213900-24-004799 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240118 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240119 DATE AS OF CHANGE: 20240119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 24545115 BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 8-K 1 ea191889-8k_inmedpharma.htm CURRENT REPORT
false 0001728328 A1 BC 0001728328 2024-01-18 2024-01-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 18, 2024

 

 

 

 

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

 

 

 

British Columbia   001-39685   98-1428279

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

InMed Pharmaceuticals Inc.

Suite 310 - 815 W. Hastings Street,

Vancouver, B.C.

Canada

   V6C 1B4
(Address of Principal Executive Offices)   (Zip Code)

 

Company’s telephone number, including area code: (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading Symbol(s)

   Name of each exchange
on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On January 18, 2024, the Company will be participating in the Water Tower Research Fireside Chat Series on January 25, 2024, at 1:00 pm ET.

 

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

The following exhibits shall be deemed to be furnished, and not filed:

 

Exhibit No.   Description
99.1   News release, dated January 18, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMED PHARMACEUTICALS INC.

 

Date: January 19, 2024 By:

/s/ Eric A Adams 

   

Eric A Adams

President & CEO

 

 

2

 

 

 EX-99.1 2 ea191889ex99-1_inmedpharma.htm NEWS RELEASE, DATED JANUARY 18, 2024

Exhibit 99.1

 

NASDAQ: INM

 

Suite 310-815 W. Hastings St.

Vancouver, BC, Canada V6C 1B4

Tel: +1.604.669.7207

Email: info@inmedpharma.com

www.inmedpharma.com

 

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in
Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

 

Vancouver, BC – January 18, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, will be participating in the Water Tower Research Fireside Chat Series on January 25, 2024, at 1:00 pm ET.

 

This event is open access for all investors. Topics will include:

 

●An overview of InMed’s pharmaceutical pipeline in Alzheimer’s and Age-related Macular Degeneration (“AMD”)

 

●A discussion of upcoming 2024 milestones in both InMed’s pharmaceutical drug development and in BayMedica’s health and wellness initiatives

 

●An overview of cannabinoids and their possible role in the treatment of Alzheimer’s

 

Interested parties can register for the event at the link below. Replays of the webcast will also be available after the event.

 

PLEASE REGISTER HERE

 

About InMed:

 

InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. Together with our subsidiary, BayMedica, we have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. We are a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.

 

About Water Tower Research:

 

Water Tower Research is a shareholder communication and engagement platform powered by senior industry experts with significant Wall Street experience. We create, deliver, and maintain the information flow required to build and preserve relationships with every stakeholder and potential investor. Our foundation is built on Wall Street veterans using open digital distribution strategies that are accessible by everyone. “Research for the Other 99%™” opens the door to reach a much broader and diverse set of investors while helping to strengthen overall communications, transparency, and engagement. For more information, visit https://www.watertowerresearch.com/home.

 

Investor Contact:

 

Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1 604 416 0999

E: cclancy@inmedpharma.com

 

Cautionary Note Regarding Forward-Looking Information:

 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: Upcoming milestones for 2024; overview of cannabinoids and their possible role in the treatment of Alzheimer’s.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

  

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^D)"@DD M#J32URM['_PE&NR:=O<:58_\?.QL>=*>B9] .M5%7);L=%]OL_\ G[@_[^"C M[?9_\_<'_?P5F#PCX? _LBUX_V*4^$?#^/^01:_]\4_<\Q>\;*LKJ&5@RGH M0<@U')=6\3;9)XD;T9P#7#ZM++X'NDAT[>@IN"2NWH)2;=DC:^W6?\ S]P?]_!4D5Q!,2(I MHY".NU@<5D_\(CX?_P"@1:_]\51U+PE:P0&\T.!;+4H/GB:(D!R/X6'0@]*2 M47U'>2Z'4450T;5(M8TN&\C&TN,.AZHXX93]#5^I:L[,I.^H4444AA1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 9/B'5'TS3?\ 1UWWMPPAMH_[ MTC=/P'6I=$TM-'TJ*T5M[C+2R'J[GEF/XUF>*TDMSINL*ADCTZ?S)D'78PVE MA].M=#%(DT22QL&1P&5AT(/0U;TBK$+XF/I"<#)Z4CNL:,[L%51DD] *Y&WL M;CQ>)[^ZO+JWTYRT=I! YCW+T\QB.N>PI1C?5[#;MHCS/XC^/8UU^W"H)H-V MT+C)2 '!=?1F/(/HOO7KG@_7!K6BHS2"2>$!79=.O_ M "S@!Y_%NE=!##'!"D,2!(T4*JCH .@K@K;2M6M/&=Y;S>()DEO(4D@F-NA\ MP*,%?8CK70?V)K?_ $,T_P#X#)6DHI)*Y$6[MV.=^( 6+5+)[3<)I4VW^Q>62]N;H;9YI^2Z M_P!W'8>U4X?#%Y8J8=-UZZM[4'Y(6C60)[ GM1)J24;[ DTV[;AXCB?3;NW\ M16R$M;#R[I%ZR0$\_BO6MFYU*UM=*?4GE!MEC\W>.XQQCZUSNL6.IZ=I%U=7 M7B:8PI&Z@1(5/_+./^!/P%=!24M9-W=S5*RL%%%%(84444 % M%%% !1110 4444 %%%% !1110 45!>W(L[&XNF4LL,;2%1U.!G'Z5YSX$^+1 M\<>)WTR+2/L<"VS3^8\V]B05&, =Z:3>HKGIM%%%(84444 8WB/3);^P6:T M.V_M'\ZV;_:'5?H1Q5K1]3BU?2X;V(;=XPZ'JCCAE/T-7ZYR;0]2LM2GN]#O M((4N6WS6UPA*;^[+CD$U:LU9D.Z=T='17/>7XN_Y^-(_[X>F26WBZ:,Q_;M, MA#<&2.)RRCVSQFCD\T'-Y$=S_P 5%XG6T'S:=I;"2;TDG_A7_@/6N?\ B5/- M%J5@(YI$!A;(1R,_,/2NYT?2H=&TY+2%FG_ /7% M_P#T(5M1:=1);&55-0;>YL?#:6271;LR2.Y%R0"[$_PCUKM*\\\%7K:;X-U: M]1 [02,X4G .$%8]Q\0]=E),;6\"^BQY_4TY493G+E%&K&$%<];HKQM?'?B$ M,#]N4^QB7'\JZGPUX^-_=QV.J1I')(=L59RO^2$U\G>$?"DWBFTUI;;<;FPL1Q['W'2KM>'_ 'Q5YD-WX7N9.8\W-IG^Z3\Z_ M@2#^)KW"LY*SL6G=&-XJ\0V_A;PU>ZQ9$_CG;A M5_ '\VKA_$OA]_!7BZPL7P((_"M8*R]2)/4^O:*BGN8 M+:UDNIY4C@C0R/(QP%4#))KPGQ)\=-3O=1-CX0L5\LMMCGEB,DDI]53L/KD_ M2LU%O8MM(][HKYMG^)/Q1\/E+G5K:5+=CTN[#8C>V0!C\Z];^'GQ'LO'5I+& M8?LNIVZ@S6^[(*G^-#W&?RH<&M1*29V]%87BSQ9IO@[1'U+4G.,[(H4^_,_9 M5_Q[5X7=_&?QOKM^T>AVD<"]5@M[8SR >Y(/\A0HM@Y)'T%KG_(OZE_UZR_^ M@&OG?X _\C[)_P!@Y_\ T)*E;XM^-]+AFL_$6G"2&YB:/]_;&W<9!&0<8/7T MJ/X!C;X_E'II\@_\>2M%%J+);NT?2U%%%8F@4444 %%%% !1110 5YG\3O\ MD)Z?_P!<7_\ 0A7IE>9_$[_D)Z?_ -<7_P#0A6^'_B(QK_ Q/#G_ "3O7OJ_ M_H K$\&QQS>*[%)45T);*L,@_*:V_#G_ "3O7OJ__H K&\$_\C?8?5__ $ U MU])_UT.;K ];GTRPNH&AFLX'C88*E!7B.K6G]F:S>6D;'_1YB$;O@\U MXEXM_P"1JU3_ *[?T%8X5OF:-<0E9,[[QI?,WPHU:\)PTFF,Q/NR?_7KS#]G M>+.JZ]+C[L$*?FS'^E=UX]E\GX'7A_O6,*?F4']:Y/\ 9UB'D>(9<<^9 OZ. M:PM:+-MVCD?&5C/\,_BO'J=@A6U:7[;;J. 48XDC_5A]"*^@]4\3V&F^#YO$ MGF![-;87$9!^_D?*/J20/QKD_C1X7_M[P2][!'NO-+)N$P.3'C]XOY<_\!KP M>[\:WMW\/+'PHVXPVURTI?/WX^J)^#%C^7I0ESI!?E9UGPAT.X\7>/[GQ'J0 M,D=G(;J1CT>X%?!%E:R) MMNYQ]INO7>PZ?@,#\*\G_:&BQXHTF3^]8LOY.?\ &FI7F#5HG1_&?Q'+!\/= M&L()"IU8(TI!ZQJ@8C\25IOP2T_0=(\.MK=[>6*:G>.RJ99D#Q1 X )R,D$ MGUXKE_BP7N/!O@*\ZHUAL)_VMD9_H:;X-^#5MXP\+VNM+KQ@:;X0A@?QKYN\%2_P#",?&6 MUM;2<26ZW[V/F*V1)&Q*@Y'7^$_A7;_\,YQ?]#&W_@&/_BJO:-\!4TC6[#41 MXA>3[)<)-Y?V4#=M(.,[N.E)5'X5[QX,\*67A'P[;:?:PJ)M@:YFQ\TLF.23]>@["OG3XE V/Q@U&6>]?/WP"Y\>RD_P#0.?\ ]"2OHC7/^1?U+_KUE_\ 0#7SO\ ?^1]D M_P"P<_\ Z$E$?A82W1]+T445F6%%%% !1110 4444 %>9_$[_D)Z?_UQ?_T( M5Z96+KFF:%>/%-K/D H"J-+-LX_,5K2FH3NS.I%RC9'&>'/^2=Z]]7_] %8W M@G_D;[#ZO_Z :](6R\/:9I:V:^5'9ZC*(54.6$KL. #SU"G\JELO"FBZ=>1W M=K9".:/.UM['&1CN:V]O&TO,R]D[Q\C9KQ'Q;_R-6J?]=OZ"O;JQ+OPCH=]= M2W-S8AYI3N=M[#)_.LJ-14Y79=6#FK(XCXG2^7\$ /\ GI':I_X\O^%9?[/" M8T/7)/[UVB_DG_UZ]0U7PUI.MZ*FCZA:":P39B(NP^[]WD'/%-\/>%]&\*VL MUMHUF+6&9_,=0[-EL8SR3V%0Y*S1:CJC6=%DC9'4,C AE(R"/2O'-,^ T-CX MK@U&35$FTV&Z\Y;0PG)4'*J6SV.,\?$>[^'MU=:5JEE/)8-+F6#&V6WD MZ$@'UQR/:OH_0K/2].T:"RT;R_L$&Z.(12;PN&.1G)Z'-9WB+P+X;\4MYFK: M7%+.!@3KE) /]Y<$_C5*2V>Q+CU1S*_'+P28MYN;Q3_<-JV?\*T_!OQ+TKQO MJ]]8Z;;7,8M8EE$DX"F0$X.%!.,\*%WT;38[>5UV/,6+.PSG!8DG%)\MM!KFZGF_P )M,@::2"+RKR)!EC&,D.!WQD@^WTK(^'WQKATG2(-)\1Q3RQ6ZA(+R$; MSL'177KQTR*]_KB]<^%/@_7KAKBXTH07#G+26KF(L?4@<'\J%)6LP:=[HP-9 M^-?@Z;2+RW@GO)99H'C55MF')4@9)Q7GGP"&/'TH/4:?)_Z$E>F1? KP7&P+ M17\@]'NCC] *ZK0/!'ASPQ*9M'TJ&VG9-C3#+.1Z;B2>PIWBE9"LV]3H**** MS+"BBB@ HHHH **** "N"\6S:7!X^T)]6M?M-O\ 8+H!/LIN,-NBP=H!]^<5 MWM95QHPG\366L^>5-K;36_E;?O>84.<10+#^Z#A)(96D5B"?F!+8*_K3O<+'-_P#"XGCMHE^SVA146&;S>A)K#6?/*FTMYH/* MVYW>84.U95QX*U-;75;#3]9MX;#5%/VA9K/?(K&,1 ML48..H4'!!Q1="U+$%_KOB/4;\Z7?6VG6-C,+<&2V\YYI-BLV?F 51N XY.# M7-W/Q#NVAOM4MM4L8TM9I$ATEK9VDN$C8JQ+C[KM@E0 0.,YYKJ?^$:U73[^ MYN-"UB&VBO"KW$%S:^:OF!0ID3#+@D*,@Y&1FBT\.:SI$TD&DZU!%ILD[3^1 M<6GF-$6; M]6?$&LWVBQ102>++"+4(K=I&B;3R_G')P6"L2BXP/S/M5F/P9;6ZTK55@ MU&W:X4R2V^^.6*64RF-EW \$C!!'?UIH\+Z_!?7E_;:Y9BYU"-$O/,L24)4% M5* ."ORG&"3TSQFC0#&M]>OY)-;U_3;'SKV;1-/N8[8 M@MYI/ Y; ).!R<> M]=5X4OY-1LY;@Z_;:Q&2 K0VXA:(]U903WMW%'"PMK?R8PJ%B"1DEF M^8\D],"AM CH****D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D! end EX-101.SCH 4 inm-20240118.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 inm-20240118_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 inm-20240118_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Jan. 18, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 18, 2024
Entity File Number 001-39685
Entity Registrant Name INMED PHARMACEUTICALS INC.
Entity Central Index Key 0001728328
Entity Tax Identification Number 98-1428279
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 310 - 815 W. Hastings Street,
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V6C 1B4
City Area Code 604)
Local Phone Number 669-7207
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol INM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 ea191889-8k_inmedpharma_htm.xml IDEA: XBRL DOCUMENT 0001728328 2024-01-18 2024-01-18 iso4217:USD shares iso4217:USD shares false 0001728328 A1 BC 8-K 2024-01-18 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 Suite 310 - 815 W. Hastings Street, Vancouver CA V6C 1B4 604) 669-7207 false false false false Common Shares, no par value INM NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea191889-8k_inmedpharma.htm inm-20240118.xsd inm-20240118_lab.xml inm-20240118_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea191889-8k_inmedpharma.htm": { "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20240118", "dts": { "inline": { "local": [ "ea191889-8k_inmedpharma.htm" ] }, "schema": { "local": [ "inm-20240118.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "inm-20240118_lab.xml" ] }, "presentationLink": { "local": [ "inm-20240118_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://inmedpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-01-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea191889-8k_inmedpharma.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-01-18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea191889-8k_inmedpharma.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001213900-24-004799-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-004799-xbrl.zip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